Intellectual Property
&
Technology Challenges
for
Biotech Industry
in
India
Ravi Dhar, Ph.D.
(rdhar_in@yahoo.com)
(
25.4.2...
Excerpts from Interview for “Protecting the
bottom line: Tackling IP barriers in
developing generic vaccines”
Vaccine Worl...
4/25/2014 RD_Vaccine Meet_2014
Acknowledgements
NIH PubMed
Scientific Community across world
DBT
NII
BIRAC
DELCON Li...
Commonly Faced Challenges
(I) IP related:
•Patents though incentives to innovation, encourage investors to
provide funds f...
(II) Possible Technology challenges
•Quality of early stage technologies & the science behind the
technology should be str...
(III) Industrial issues
(i) Increased regulatory review times, as well
as increasing requirements for compliance
with safe...
(IV) Art of Negotiations
•Vaccine development & production require an
art of negotiations in acquiring a license which is
...
(V) Other Issues
•Long time taken for Regulatory approvals
•Dependence on Government to push volumes
•Funding for clinical...
Suggestions to Players facing such Challenges?
• Develop Technology Transfer office hubs with highly trained
managers to s...
Most Common Complications Encountered by
Industry and How can these be Avoided?
• Vaccine development & manufacture is a c...
Three(3) most Important Factors to Consider
before Filing for a Patent?
• Market analysis to check assured market for whic...
Tips to Ensure Protection of Intellectual
Property:
•Ensure IP leakage does not happen, if it does, take an
appropriate le...
Expectations?
“Each country has its specific health & financial issues. For
developing or under-developed countries, socie...
“We also need to educate people about Health care
benefits due to drugs & vaccines. Public-private
partnerships have shown...
4/25/2014 RD_Vaccine Meet_2014 15
Thanks
(rdhar_in@yahoo.com)
Upcoming SlideShare
Loading in …5
×

Dr. Ravi Dhar on "Technology Barriers & Intellectual Property" Interview 2014

668 views

Published on

Published in: Health & Medicine
1 Comment
0 Likes
Statistics
Notes
  • Be the first to like this

No Downloads
Views
Total views
668
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
9
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

Dr. Ravi Dhar on "Technology Barriers & Intellectual Property" Interview 2014

  1. 1. Intellectual Property & Technology Challenges for Biotech Industry in India Ravi Dhar, Ph.D. (rdhar_in@yahoo.com) ( 25.4.2014 (Mobile: 987-162-0439) Immediate Past Affiliation: BIRAC-DBT, GoI, India Past Affiliations: University of Kashmir, India University of Delhi, India National Institute of Immunology, India Johns Hopkins University, U.S.A. LSU, U.S.A. OTT, Boston University, U.S.A. OTT, NIH, U.S.A. 4/25/2014 1RD_Vaccine Meet_2014
  2. 2. Excerpts from Interview for “Protecting the bottom line: Tackling IP barriers in developing generic vaccines” Vaccine World Summit-2014, Hyderabad, India 4/25/2014 RD_Vaccine Meet_2014 2
  3. 3. 4/25/2014 RD_Vaccine Meet_2014 Acknowledgements NIH PubMed Scientific Community across world DBT NII BIRAC DELCON Library Services Dr. M.K. Bhan Various Websites Nature Biotechnology & other Journals OTT, Boston University Dr. Jerry Keusch Dr. Ashley Stevens OTT, NIH 3
  4. 4. Commonly Faced Challenges (I) IP related: •Patents though incentives to innovation, encourage investors to provide funds for development of drugs and vaccines. However, they also block developers or manufacturers from entering a particular domain & hence block collaboration between entities holding an IP e.g., type of claims on individual components of a vaccine •In case of patents on vaccines with multiple owners (although these patents are related to each other), conflicts of various sorts arise due to strength or weakness or perception of Patent Claims. •IP leakages have been reported in several instances, these should be blocked. •Manufacturers should relook at use of Patent pools, as these may be useful. 4/25/2014 4RD_Vaccine Meet_2014
  5. 5. (II) Possible Technology challenges •Quality of early stage technologies & the science behind the technology should be strong and should pass the validation stage •Enable strong technology scouting mechanisms & develop capacity to locate a partner for transfer or upscaling •Translational issues due to lack of skilled manpower, funding, equipment etc. •Need for improved cGMP practices •Lack of basic infrastructure (cold chain and other) •Lack of precise long-term forecasting •Financial and logistical hurdles (country willingness and ability to pay) •Political choices •Limited Capacity building effort 4/25/2014 5RD_Vaccine Meet_2014
  6. 6. (III) Industrial issues (i) Increased regulatory review times, as well as increasing requirements for compliance with safety and efficacy standards (ii) Global variations in regulatory approval requirements (iii) Skyrocketing R&D costs 4/25/2014 6RD_Vaccine Meet_2014
  7. 7. (IV) Art of Negotiations •Vaccine development & production require an art of negotiations in acquiring a license which is related to size of companies. •Negotiations become more complex when one has to deal with big companies. •This faculty needs to be enhanced by Indian academia & industry. 4/25/2014 7RD_Vaccine Meet_2014
  8. 8. (V) Other Issues •Long time taken for Regulatory approvals •Dependence on Government to push volumes •Funding for clinical trials •Lack of institutional IP & Tech management policy & personnel •Limits in number of industry skilled personnel •Non-availability of adjuvants for use in vaccine development •Quality assurance & maintenance •Taxation issues •Data exclusivity •Lack of access to paid Patent sites for Prior art searches •Regulatory inconveniences •Lack of adequate Market analysis tools 4/25/2014 8RD_Vaccine Meet_2014
  9. 9. Suggestions to Players facing such Challenges? • Develop Technology Transfer office hubs with highly trained managers to support & handle various IP or technology management issues •Indulge in more active collaborations to learn from experiences of other Manufacturers •Serious interactions with DCGI, Health ministry, DBT, BIRAC, ICMR, CSIR etc so as to help each other devise effective policies to face challenges •Workshops on Regulatory issues to highlight various issues •More active collaborations to develop alternate vaccine development processes free from IP regulations •Indulge in Public Private Partnerships 4/25/2014 9RD_Vaccine Meet_2014
  10. 10. Most Common Complications Encountered by Industry and How can these be Avoided? • Vaccine development & manufacture is a complex and well regulated process which needs great awareness about IP, Technology development& art of negotiations • Awareness about implementation & design of limited clinical trials • Careful framing of agreement including Royalty issues •Press for speedy Regulatory approvals by DCGI •Conduct carefully designed R&D to circumvent IP issues related to vaccine or therapeutic production •R&D related to identifying/developing new adjuvants •Funding is essential requirement for R&D, so manufacturers should look for Venture Funding to achieve above goals 4/25/2014 10RD_Vaccine Meet_2014
  11. 11. Three(3) most Important Factors to Consider before Filing for a Patent? • Market analysis to check assured market for which one needs to use all patent information tools •A vaccine manufacturer should conduct Freedom to operate analysis •Prior art searches & Valuations are essential •One should analyse the possible Regulatory hassles •In case a manufacturer has procured a license for manufacturing a vaccine or a drug, it should be ensured that patent filing & maintenance funds are available 4/25/2014 11RD_Vaccine Meet_2014
  12. 12. Tips to Ensure Protection of Intellectual Property: •Ensure IP leakage does not happen, if it does, take an appropriate legal action • Stage at which one should discuss one’s invention • No public disclosure of IP without legal protection •Careful drafting of patent claims & retention of “know-how” •Careful monitoring of market trends • Due diligence for possible infringement as per laws of the land or WTO regulations 4/25/2014 12RD_Vaccine Meet_2014
  13. 13. Expectations? “Each country has its specific health & financial issues. For developing or under-developed countries, societal good is a priority. So generics are essential. I also believe that companies do not live for charities, yet what we need is to design strategies to develop affordable drugs (like corpus funds for R&D by philanthropists, NGOs, Companies, common man) for developing generic & branded vaccines.” (R.D.) 4/25/2014 13RD_Vaccine Meet_2014
  14. 14. “We also need to educate people about Health care benefits due to drugs & vaccines. Public-private partnerships have shown encouraging results in various areas of governance in different parts of world. We are hopeful that it will be beneficial for drug development in India in the long run. Such partnerships are necessary as they complement each others’ competencies & capacities. (Note: I also want to point out that the viewpoints given here do not reflect the organizational or Government view point, but are based on my experience or research” (Ravi Dhar_2014) 4/25/2014 14RD_Vaccine Meet_2014
  15. 15. 4/25/2014 RD_Vaccine Meet_2014 15 Thanks (rdhar_in@yahoo.com)

×